Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416

Molecular Pharmaceutics

Volumn 9, Issue 12, 2012, Pages 3486-3494

  Yoshizawa, Yuta ^a   Ogawara, Ken Ichi ^a   Fushimi, Aya ^a   Abe, Shigeki ^a   Ishikawa, Keisuke ^a   Araki, Tomoya ^a   Molema, Grietje ^b   Kimura, Toshikiro ^a   Higaki, Kazutaka ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

angiogenesis; drug delivery; paclitaxel; PEG liposome; VEGF

Indexed keywords

CREMOPHOR; LIPOSOME; MACROGOL; PACLITAXEL; SEMAXANIB;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TISSUE; COLON TUMOR; DRUG DISPOSITION; DRUG SOLUBILITY; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; OXYGEN SUPPLY; PERICYTE; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COLONIC NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLES; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PERICYTES; POLYETHYLENE GLYCOLS; PYRROLES; SOLUBILITY; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84870530607     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300318q     Document Type: Article

References (51)

1. Jain, R. K. Barriers to drug delivery in solid tumors Sci. Am. 1994, 271, 58-65
2. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases Nature 2000, 407, 249-257
3. Gazit, Y.; Baish, J. W.; Safabakhsh, N.; Leunig, M.; Baxter, L. T.; Jain, R. K. Fractal characteristics of tumor vascular architecture during tumor growth and regression Microcirculation 1997, 4, 395-402 (Pubitemid 127675113)
4. Morikawa, S.; Baluk, P.; Kaidoh, T.; Haskell, A.; Jain, R. K.; McDonald, D. M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors Am. J. Pathol. 2002, 160, 985-1000 (Pubitemid 34224587)
5. Inai, T.; Mancuso, M.; Hashizume, H.; Baffert, F.; Haskell, A.; Baluk, P.; Hu-Lowe, D. D.; Shalinsky, D. R.; Thurston, G.; Yancopoulos, G. D.; McDonald, D. M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts Am. J. Pathol. 2004, 165, 35-52 (Pubitemid 38821812)
6. Yuan, F.; Leunig, M.; Huang, S. K.; Berk, D. A.; Papahadjopoulos, D.; Jain, R. K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res. 1994, 54, 3352-3356 (Pubitemid 24225946)
7. Campbell, R. B.; Fukumura, D.; Brown, E. B.; Mazzola, L. M.; Izumi, Y.; Jain, R. K.; Torchilin, V. P.; Munn, L. L. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors Cancer Res. 2002, 62, 6831-6836 (Pubitemid 35424069)
8. Padera, T. P.; Stoll, B. R.; Tooredman, J. B.; Capen, D.; di Tomaso, E.; Jain, R. K. Pathology: cancer cells compress intratumour vessels Nature 2004, 427, 695 (Pubitemid 38294577)
9. Jain, R. K.; Tong, R. T.; Munn, L. L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model Cancer Res. 2007, 67, 2729-2735 (Pubitemid 46548961)
10. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 2005, 307, 58-62 (Pubitemid 40093472)
11. Fukumura, D.; Jain, R. K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization Microvasc. Res. 2007, 74, 72-84 (Pubitemid 350051025)
12. Homsi, J.; Daud, A. I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors Cancer Control 2007, 14, 285-294 (Pubitemid 47057799)
13. Dickson, P. V.; Hamner, J. B.; Sims, T. L.; Fraga, C. H.; Ng, C. Y.; Rajasekeran, S.; Hagedorn, N. L.; McCarville, M. B.; Stewart, C. F.; Davidoff, A. M. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy Clin. Cancer Res. 2007, 13, 3942-3950 (Pubitemid 47037602)
14. Kano, M. R.; Komuta, Y.; Iwata, C.; Oka, M.; Shirai, Y. T.; Morishita, Y.; Ouchi, Y.; Kataoka, K.; Miyazono, K. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature Cancer Sci. 2009, 100, 173-180
15. Ohta, M.; Kawabata, T.; Yamamoto, M.; Tanaka, T.; Kikuchi, H.; Hiramatsu, Y.; Kamiya, K.; Baba, M.; Konno, H. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model Surg. Today 2009, 39, 1046-1053
16. Tailor, T. D.; Hanna, G.; Yarmolenko, P. S.; Dreher, M. R.; Betof, A. S.; Nixon, A. B.; Spasojevic, I.; Dewhirst, M. W. Effect of pazopanib on tumor microenvironment and liposome delivery Mol. Cancer Ther. 2010, 9, 1798-1808
17. Tong, R. T.; Boucher, Y.; Kozin, S. V.; Winkler, F.; Hicklin, D. J.; Jain, R. K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res. 2004, 64, 3731-3736 (Pubitemid 38697278)
18. Winkler, F.; Kozin, S. V.; Tong, R. T.; Chae, S. S.; Booth, M. F.; Garkavtsev, I.; Xu, L.; Hicklin, D. J.; Fukumura, D.; di Tomaso, E.; Munn, L. L.; Jain, R. K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 2004, 6, 553-563 (Pubitemid 40017699)
19. Ansiaux, R.; Baudelet, C.; Jordan, B. F.; Crokart, N.; Martinive, P.; DeWever, J.; Grégoire, V.; Feron, O.; Gallez, B. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy Cancer Res. 2006, 66, 9698-9704 (Pubitemid 44623670)
20. Bäckman, U.; Svensson, A.; Christofferson, R. Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma Angiogenesis 2002, 5, 267-274 (Pubitemid 36875125)
21. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 2001, 37, 1590-1598 (Pubitemid 32778603)
22. Eskens, F. A.; Verweij, J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review Eur. J. Cancer 2006, 42, 3127-3139 (Pubitemid 44869016)
23. Fong, T. A.; Shawver, L. K.; Sun, L.; Tang, C.; App, H.; Powell, T. J.; Kim, Y. H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K. P.; McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types Cancer Res. 1999, 59, 99-106 (Pubitemid 29062964)
24. Giles, F. J.; Cooper, M. A.; Silverman, L.; Karp, J. E.; Lancet, J. E.; Zangari, M.; Shami, P. J.; Khan, K. D.; Hannah, A. L.; Cherrington, J. M.; Thomas, D. A.; Garcia-Manero, G.; Albitar, M.; Kantarjian, H. M.; Stopeck, A. T. Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases Cancer 2003, 97, 1920-1928 (Pubitemid 36397267)
25. Yoshizawa, Y.; Kono, Y.; Ogawara, K.; Kimura, T.; Higaki, K. PEG liposomalization of paclitaxel improved its in-vivo disposition and anti-tumor efficacy Int. J. Pharm. 2011, 412, 132-141
26. Lee, E. S.; Na, K.; Bae, Y. H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor J. Controlled Release 2005, 103, 405-418 (Pubitemid 40342538)
27. Horowitz, A.; Simons, M. Branching morphogenesis Circ. Res. 2008, 103, 784-795
28. Carmeliet, P.; Ferreira, V.; Breier, G.; Pollefeyt, S.; Kieckens, L.; Gertsenstein, M.; Fahrig, M.; Vandenhoeck, A.; Harpal, K.; Eberhardt, C.; Declercq, C.; Pawling, J.; Moons, L.; Collen, D.; Risau, W.; Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele Nature 1996, 380, 435-439 (Pubitemid 26102719)
29. Ellis, L. M.; Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity Nat. Rev. Cancer 2008, 8, 579-591
30. Crawford, Y.; Ferrara, N. VEGF inhibition: insights from preclinical and clinical studies Cell Tissue Res. 2009, 335, 261-269
31. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 2000, 65, 271-284 (Pubitemid 30122932)
32. Folkman, J. Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 1971, 285, 1182-1186
33. Díaz-Flores, L.; Gutiérrez, R.; Madrid, J. F.; Varela, H.; Valladares, F.; Acosta, E.; Martín-Vasallo, P.; Díaz-Flores, L., Jr. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche Histol. Histopathol. 2009, 24, 909-969
34. Ozawa, M. G.; Yao, V. J.; Chanthery, Y. H.; Troncoso, P.; Uemura, A.; Varner, A. S.; Kasman, I. M.; Pasqualini, R.; Arap, W.; McDonald, D. M. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma Cancer 2005, 104, 2104-2115 (Pubitemid 41579956)
35. Baluk, P.; Hashizume, H.; McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer Curr. Opin. Genet. Dev. 2005, 15, 102-111 (Pubitemid 40127638)
36. Kalluri, R.; Zeisberg, M. Fibroblasts in cancer Nat. Rev. Cancer 2006, 6, 392-401
37. Erber, R.; Thurnher, A.; Katsen, A. D.; Groth, G.; Kerger, H.; Hammes, H. P.; Menger, M. D.; Ullrich, A.; Vajkoczy, P. Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericytes-mediated endothelial survival mechanisms FASEB J. 2003, 18, 338-340
38. Kaluz, S.; Kaluzová, M.; Liao, S. Y.; Lerman, M.; Stanbridge, E. J. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim. Biophys. Acta 2009, 1795, 162-172
39. Stohrer, M.; Boucher, Y.; Stangassinger, M.; Jain, R. K. Oncotic pressure in solid tumors is elevated Cancer Res. 2000, 60, 4251-4255 (Pubitemid 30636613)
40. Padera, T. P.; Stoll, B. R.; Tooredman, J. B.; Capen, D.; di Tomaso, E.; Jain, R. K. Pathology: cancer cells compress intratumour vessels Nature 2004, 427, 695 (Pubitemid 38294577)
41. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation Nat. Med. 1997, 3, 177-182 (Pubitemid 27064702)
42. Greenberg, J. I.; Shields, D. J.; Barillas, S. G.; Acevedo, L. M.; Murphy, E.; Huang, J.; Scheppke, L.; Stockmann, C.; Johnson, R. S.; Angle, N.; Cheresh, D. A. A role for VEGF as a negative regulator of pericyte function and vessel maturation Nature 2008, 456, 809-813
43. Thurston, G.; Rudge, J. S.; Ioffe, E.; Zhou, H.; Ross, L.; Croll, S. D.; Glazer, N.; Holash, J.; McDonald, D. M.; Yancopoulos, G. D. Angiopoietin-1 protects the adult vasculature against plasma leakage Nat. Med. 2000, 6, 460-463 (Pubitemid 30208166)
44. Saharinen, P.; Eklund, L.; Miettinen, J.; Wirkkala, R.; Anisimov, A.; Winderlich, M.; Nottebaum, A.; Vestweber, D.; Deutsch, U.; Koh, G. Y.; Olsen, B. R.; Alitalo, K. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts Nat. Cell Biol. 2008, 10, 527-537 (Pubitemid 351627372)
45. Augustin, H. G.; Koh, G. Y.; Thurston, G.; Alitalo, K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system Nat. Rev. Mol. Cell Biol. 2009, 10, 165-177
46. Stoeltzing, O.; Ahmad, S. A.; Liu, W.; McCarty, M. F.; Wey, J. S.; Parikh, A. A.; Fan, F.; Reinmuth, N.; Kawaguchi, M.; Bucana, C. D.; Ellis, L. M. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors Cancer Res. 2003, 63, 3370-3377 (Pubitemid 36735897)
47. Gaengel, K.; Genové, G.; Armulik, A.; Betsholtz, C. Endothelial-mural cell signaling in vascular development and angiogenesis Arterioscler., Thromb., Vasc. Biol. 2009, 29, 630-638
48. Jain, R. K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 2010, 7, 653-664
49. Griffin, R. J.; Molema, G.; Dings, R. P. Angiogenesis treatment, new concepts on the horizon Angiogenesis 2006, 9, 67-72 (Pubitemid 44440551)
50. Ogawara, K.; Un, K.; Minato, K.; Tanaka, K.; Higaki, K.; Kimura, T. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors Int. J. Pharm. 2008, 359, 234-240
51. Chauhan, V. P.; Stylianopoulos, T.; Martin, J. D.; Popović, Z.; Chen, O.; Kamoun, W. S.; Bawendi, M. G.; Fukumura, D.; Jain, R. K. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner Nat. Nanotechnol. 2012, 7, 383-388